Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Ulcerative Colitis
Last updated:
December 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Crohn's disease
Last updated:
December 19, 2025
Myfembree (relugolix, estradiol, and norethindrone acetate)
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Management of heavy menstrual bleeding associated with uterine fibroids
Last updated:
December 12, 2025
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Last updated:
December 11, 2025
Omnipod 5 (Automated Insulin Delivery System)
Status:
Concluded with an LOI
Manufacturer:
Insulet Canada Corporation
Indication:
Patients with Type 1 Diabetes aged 2 years and old
Last updated:
December 11, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated:
December 10, 2025
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Last updated:
December 3, 2025
Status:
Negotiations were not pursued (Manufacturer withdrew from negotiation)
Manufacturer:
Amgen Canada Inc.
Indication:
Advanced non-small cell lung cancer, KRAS G12C-mutated
Last updated:
December 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Last updated:
December 1, 2025
Status:
Concluded without agreement (Manufacturer declined negotiation)
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Last updated:
December 1, 2025